CRISPR DNA Editing Can Cause Hundreds of Off-Target Mutations
By Dave Roos,
Seeker [cites Marcy Darnovsky]
| 06. 06. 2017
A new study offers a cautionary tale for using the widely hyped gene-editing tool CRISPR on people.
The gene-editing technology known as CRISPR has only been around for five years, but it’s already generated enough hype and controversy to last a lifetime. Compared to other gene-editing techniques, CRISPR is so fast, cheap, and precise that any scientist with a basic understanding of genetics can experiment with DNA — plant, animal, or human — by cutting out and replacing specific genes.
Some say that the ease and effectiveness of CRISPR will usher in a golden age of genetic modification resulting in new cures for inherited diseases like Huntington’s and muscular dystrophy and new gene therapies for eradicating cancer and HIV. Others see CRISPR as a Pandora’s box leading to a dystopian future of designer babies and expensive life-extending therapies that will further divide the world into genetic haves and have nots.
Now a new study complicates the CRISPR controversy by shining a light on CRISPR’s Achilles' heel — off-target mutations. CRISPR works by targeting short sequences of DNA base pairs in...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...